DTC
NRIX icon

Deep Track Capital’s Nurix Therapeutics NRIX Stock Holding History

Deep Track Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188M Buy
7,736,455
+1,391,211
+22% +$23.7M 2.73% 12
2026
Q1 		$98.4M Sell
6,345,244
-691,211
-10% -$11.5M 1.61% 19
2025
Q4 		$133M Buy
7,036,455
+979,431
+16% +$14.1M 2.38% 15
2025
Q3 		$56M Sell
6,057,024
-7,886
-0.1% -$81.9K 1.56% 21
2025
Q2 		$69.1M Buy
6,064,910
+564,910
+10% +$6.1M 2.22% 17
2025
Q1 		$65.3M Buy
5,500,000
+2,500,000
+83% +$41.8M 2.12% 16
2024
Q4 		$56.5M Sell
3,000,000
-868,104
-22% -$19.9M 2.11% 13
2024
Q3 		$86.9M Sell
3,868,104
-123,396
-3% -$2.8M 2.76% 14
2024
Q2 		$83.3M Buy
3,991,500
+993,670
+33% +$15.5M 2.49% 17
2024
Q1 		$44.1M Hold
2,997,830
– – 1.26% 31
2023
Q4 		$30.9M Hold
2,997,830
– – 1.03% 39
2023
Q3 		$23.6M Hold
2,997,830
– – 0.91% 34
2023
Q2 		$29.9M Hold
2,997,830
– – 1.39% 22
2023
Q1 		$26.6M Buy
2,997,830
+731,261
+32% +$7.62M 1.09% 32
2022
Q4 		$24.9M Buy
2,266,569
+212,948
+10% +$2.57M 1.04% 35
2022
Q3 		$26.8M Sell
2,053,621
-382,543
-16% -$6.05M 1.23% 31
2022
Q2 		$30.9M Buy
+2,436,164
New +$27.6M 2.03% 20

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Deep Track Capital's NRIX Position: Q2 2026 in Review

Deep Track Capital increased its Nurix Therapeutics (NRIX) stake by 22% in Q2 2026, buying an estimated $23.7M and bringing the position to 7,736,455 shares worth $188M. The position accounts for 2.73% of the portfolio, ranked #12.

Deep Track Capital first reported a position in NRIX in Q2 2022 and has held it in 17 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Deep Track Capital held 7,736,455 shares of Nurix Therapeutics worth $188M as of Q2 2026.
  • Deep Track Capital bought 1,391,211 Nurix Therapeutics shares in Q2 2026, an estimated $23.7M.
  • Nurix Therapeutics made up 2.73% of Deep Track Capital's portfolio in Q2 2026, its #12 holding.
  • Deep Track Capital first reported a position in Nurix Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.